High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.

  title={High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.},
  author={Alex Pearson and Elizabeth C Smyth and Irina S. Babina and Maria Teresa Herrera-Abreu and Noelia Tarazona and Clare Peckitt and Elaine Kilgour and Neil R. Smith and Catherine Geh and Claire Rooney and Rosalind J. Cutts and James Campbell and Jian Ning and Kerry Fenwick and Amanda Swain and Gina Brown and Sue Chua and Anne L. Thomas and Stephen R. D. Johnston and Mazhar Ajaz and Kate A Sumpter and Angela Gillbanks and David J Watkins and Ian Chau and Sanjay Popat and David Cunningham and Nicholas C. Turner},
  journal={Cancer discovery},
  volume={6 8},
UNLABELLED FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level clonal FGFR2 amplification have a high response rate to the selective FGFR inhibitor AZD4547, whereas cancers with subclonal or low-level amplification did not respond. Using cell lines and patient-derived xenograft models, we show that high-level FGFR2 amplification… 

Figures from this paper

Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer

The roles of alternative receptor tyrosine kinases (RTKs) in FGFR1-amplified lung cancer are identified and suggest that incomplete suppression of key survival signals led to intrinsic and acquired resistance to FGFR inhibitors.

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

This preclinical study confirmed pharmacodynamics and identified new predictive biomarkers to FGFR inhibition with erdafitinib and supports further clinical evaluation of this compound in patients with FGFR genetic alterations.

High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

Tailored therapy with FGFRis in molecularly selected MBC based on high FGFR1–4 mRNA levels warrants prospective validation in patients with CDK4/6i-resistant luminal breast cancer and in Patients with TNBC without targeted therapeutic options.

Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.

The first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC are reported, which can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target.

Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK

Preclinical analyses revealed FGFR-driven gastric cancer cell lines rapidly reactivate MAPK/ERK signaling in response to FGFR inhibition, which may underlie the limited clinical response to regorafenib.

FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.

  • L. WeinP. Savas S. Loi
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2017
This case report describes a patient with estrogen receptor (ER)positive metastatic breast cancer with a high level FGFR2 gene amplification who demonstrated a significant clinical benefit to an mTOR inhibitor, everolimus with exemestane.

EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.

The findings reveal EGFR-dependent adaptive signaling as an important mechanism limiting FGFR inhibitor efficacy and driving resistance and support clinical testing of FGFR/EGFR inhibitor therapy for FGFR2 fusion-positive cholangiocarcinoma.

Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer

Evidence is provided for the existence of diverse mechanisms of primary drug resistance in FGFR1-amplified lung cancer and a rational strategy to improve FGFR inhibitor therapies by combination treatment is provided.

Acquired JHDM1D–BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer

The data provide a clinical rationale for using a MEK or RAF dimer inhibitor to treat FGFR2-amplified gastric cancer patients who have acquired resistance through the JHDN1D–BRAF fusion.

A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer

It is demonstrated that targeting ILK would enhance the effectiveness of AZD4547 treatment of gastric tumors with amplifications of FGFR2, and for the first time, that GSK3b is one of the downstream effectors of ILK upon FGFR inhibition.



FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

It is revealed that both the FGFR2 and EGFR family signaling pathways are activated inFGFR2-amplified gastric cancer cell lines to drive cell proliferation and survival.

Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.

Using parallel RNA interference genetic screens, the role of EGFR is extended in mediating resistance to inhibitors targeting a mutant oncogene, showing that EGFR signaling can repress mutant FGFR3 to induce intrinsic resistance to FGFR targeting.

AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.

The findings show that AZD4547 is a novel selective small-molecule inhibitor of FGFR with potent antitumor activity against FGFR-deregulated tumors in preclinical models and is under clinical investigation for the treatment ofFGFR-dependent tumors.

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo

Results indicate that inhibition of FGFR1 and wild-type or mutant FGFR3 may represent a useful therapeutic approach in patients with both non-muscle invasive and muscle invasive UC.

Comprehensive molecular characterization of gastric adenocarcinoma

A comprehensive molecular evaluation of 295 primary gastric adenocarcinomas as part of The Cancer Genome Atlas (TCGA) project is described and a molecular classification dividing gastric cancer into four subtypes is proposed.

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

Efforts are being pursued to develop selective approaches for use against FGF/FGFR by optimizing the management of emerging, class-specific toxicity profiles and correctly designing clinical trials to address these different issues.

Aberrant Receptor Internalization and Enhanced FRS2-dependent Signaling Contribute to the Transforming Activity of the Fibroblast Growth Factor Receptor 2 IIIb C3 Isoform*

The data support a dual mechanism where deletion of the 770YXXL773 motif promotes FGFR2 IIIb C3 transforming activity by causing aberrant receptor recycling and stability and persistent FRS2-dependent signaling.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.

Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs.

Sequence analysis of the DNA sequences surrounding the deletion junctions shows the presence of unique sequences and indicates the involvement of short homology-mediated recombination in the generation of these deletions.

Fibroblast growth factor signalling: from development to cancer

There is now substantial evidence for the importance of FGF signalling in the pathogenesis of diverse tumour types, and clinical reagents that specifically target the FGFs or FGF receptors are being developed.